基因型HIV DNA检测的应用:一项德尔菲型共识
法国开展德尔菲型共识,基于文献回顾与临床经验制定20条声明,经21名病毒学家和47名临床医生两轮投票,18/20条(90%)达成强烈共识,旨在统一HIV DNA测序的临床使用、技术和结果解读。
要点
- 当RNA数据不可用、不可利用或信息不足时,既往HIV DNA基因型可用于考虑换用某些长效方案或减少抗逆转录病毒药物数量的临床决策。
- 20条声明中18条(90%)达成强烈共识,2条未达成共识。
- 未达成共识的两条分别涉及:报告任何检测到的病毒 minority 群体供多学科会议讨论(病毒学家),以及在病毒载量检测不到≥1年且近5年内有 documented M184V 突变的患者中使用第二代InSTI联合拉米夫定或恩曲他滨方案可能出现病毒学失败的风险(临床医生)。
核心结论
- 该德尔菲型共识将有助于加强和统一HIV DNA测序的良好实践。
研究设计与样本
- 由八名病毒学家和一名传染病专家组成的指导委员会基于文献回顾和临床经验制定声明。
- 声明于2022年10月至2022年12月期间提交给法国病毒学家和HIV临床医生进行独立匿名电子投票。
- 21名病毒学家和47名临床医生参与了两轮投票。
主要发现
- 指导委员会制定了20条声明,分为六个类别:HIV DNA基因分型使用的临床情况、执行HIV DNA基因分型的技术、载脂蛋白B mRNA编辑酶(APOBEC)突变的考虑、基因分型结果报告、抗逆转录病毒药物的再利用、HIV DNA基因分型检测的可及性和延迟。
- 18/20条(90%)声明达成「强烈」共识。
- 两条声明未达成共识:报告任何检测到的病毒 minority 群体供多学科会议讨论(病毒学家),以及在病毒载量检测不到≥1年且近5年内有 documented M184V 突变的患者中使用第二代InSTI联合拉米夫定或恩曲他滨方案可能出现病毒学失败的风险(临床医生)。
关键数值与推荐
- 当考虑换用某些长效方案或在病毒学抑制但RNA数据不可用、不可利用或信息不足的患者中减少抗逆转录病毒药物数量时,既往HIV DNA基因分型对临床决策有用(达成强烈共识)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results. METHODS: Based on a literature review and clinical experience, a steering committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October 2022 and December 2022. RESULTS: The SC developed 20 statements grouped into six categories: clinical situations for the use of HIV DNA genotyping; techniques for performing HIV DNA genotyping; consideration of apolipoprotein B mRNA editing enzyme (APOBEC) mutations; genotyping results reporting; recycling of antiretrovirals; and availability of HIV DNA genotyping tests and delays. Twenty-one virologists and 47 clinicians participated in two voting rounds and 18/20 (90%) assertions reached a 'strong' consensus. For example, that prior genotyping on HIV DNA is useful for clinical decision-making when considering switching to some long-acting regimens or to reduce the number of antiretroviral agents in virologically suppressed patients for whom RNA data are unavailable/not exploitable/not sufficiently informative. Two statements achieved no consensus: reporting any detected viral minority population for discussion in multidisciplinary meetings (virologists), and possible risk of virological failure when using a second-generation InSTI plus lamivudine or emtricitabine regimen in patients with undetectable viral load within ≥1 year and in the presence of a documented M184V mutation within the last 5 years (clinicians). CONCLUSIONS: This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.
引用
- Andre-Garnier E, Bocket L, Bourlet T, et al. Use of genotypic HIV DNA testing: a DELPHI-type consensus. J Antimicrob Chemother. 2024. PMID: 38269616. doi:10.1093/jac/dkae007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。